Literature DB >> 12897767

Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity.

Catherine E Fitzgerald1, Sangita B Patel, Joseph W Becker, Patricia M Cameron, Dennis Zaller, Vasilis Bill Pikounis, Stephen J O'Keefe, Giovanna Scapin.   

Abstract

The quinazolinone and pyridol-pyrimidine classes of p38 MAP kinase inhibitors have a previously unseen degree of specificity for p38 over other MAP kinases. Comparison of the crystal structures of p38 bound to four different compounds shows that binding of the more specific molecules is characterized by a peptide flip between Met109 and Gly110. Gly110 is a residue specific to the alpha, beta and gamma isoforms of p38. The delta isoform and the other MAP kinases have bulkier residues in this position. These residues would likely make the peptide flip energetically unfavorable, thus explaining the selectivity of binding. To test this hypothesis, we constructed G110A and G110D mutants of p38 and measured the potency of several compounds against them. The results confirm that the selectivity of quinazolinones and pyridol-pyrimidines results from the presence of a glycine in position 110. This unique mode of binding may be exploited in the design of new p38 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12897767     DOI: 10.1038/nsb949

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  30 in total

1.  Effects of Water Placement on Predictions of Binding Affinities for p38α MAP Kinase Inhibitors.

Authors:  James Luccarelli; Julien Michel; Julian Tirado-Rives; William L Jorgensen
Journal:  J Chem Theory Comput       Date:  2010-01-01       Impact factor: 6.006

2.  Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK.

Authors:  Natalie B Vinh; Jamie S Simpson; Peter J Scammells; David K Chalmers
Journal:  J Comput Aided Mol Des       Date:  2012-04-20       Impact factor: 3.686

3.  Towards a better understanding of the substrate specificity of the UDP-N-acetylglucosamine C4 epimerase WbpP.

Authors:  Melinda Demendi; Noboru Ishiyama; Joseph S Lam; Albert M Berghuis; Carole Creuzenet
Journal:  Biochem J       Date:  2005-07-01       Impact factor: 3.857

4.  Outliers in SAR and QSAR: 2. Is a flexible binding site a possible source of outliers?

Authors:  Ki Hwan Kim
Journal:  J Comput Aided Mol Des       Date:  2007-07-24       Impact factor: 3.686

5.  Versatile loops in mycocypins inhibit three protease families.

Authors:  Miha Renko; Jerica Sabotic; Marko Mihelic; Joze Brzin; Janko Kos; Dusan Turk
Journal:  J Biol Chem       Date:  2009-10-21       Impact factor: 5.157

6.  Pharmacophore modeling using site-identification by ligand competitive saturation (SILCS) with multiple probe molecules.

Authors:  Wenbo Yu; Sirish Kaushik Lakkaraju; E Prabhu Raman; Lei Fang; Alexander D MacKerell
Journal:  J Chem Inf Model       Date:  2015-02-06       Impact factor: 4.956

7.  Spatial analysis and quantification of the thermodynamic driving forces in protein-ligand binding: binding site variability.

Authors:  E Prabhu Raman; Alexander D MacKerell
Journal:  J Am Chem Soc       Date:  2015-02-16       Impact factor: 15.419

8.  Structural basis of p38α regulation by hematopoietic tyrosine phosphatase.

Authors:  Dana M Francis; Bartosz Różycki; Dorothy Koveal; Gerhard Hummer; Rebecca Page; Wolfgang Peti
Journal:  Nat Chem Biol       Date:  2011-11-06       Impact factor: 15.040

9.  p38 mitogen-activated protein kinase controls NF-kappaB transcriptional activation and tumor necrosis factor alpha production through RelA phosphorylation mediated by mitogen- and stress-activated protein kinase 1 in response to Borrelia burgdorferi antigens.

Authors:  Chris M Olson; Michael N Hedrick; Hooman Izadi; Tonya C Bates; Elias R Olivera; Juan Anguita
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

10.  Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors.

Authors:  David E Heppner; Marcel Günther; Florian Wittlinger; Stefan A Laufer; Michael J Eck
Journal:  J Med Chem       Date:  2020-04-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.